 Syros Pharmaceuticals Inc NASDAQ: SYRS announced new preclinical data from its CDK12 inhibitor program, demonstrating robust anti-tumor activity in models of breast, lung, and ovarian cancer, including in a PARP inhibitor-resistant model. The data support the advancement of. 